Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100028 | 0.90 | CHRM3 (0.83) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4105886 | 0.90 | CHRM3 (0.83) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4112329 | 0.90 | CHRM3 (0.83) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4096247 | 0.90 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4104416 | 0.88 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4093731 | 0.88 | CHRM3 (0.66) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4110625 | 0.88 | CHRM3 (0.65) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4104558 | 0.86 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4054802 | 0.86 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4101080 | 0.86 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | claimed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| EP-1725236-A4 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1725236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM2 2/4885CHRM1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.